The Simpson Querrey Lung Institute for Translational Science (SQLIFTS) at Northwestern University Feinberg School of Medicine is developing innovative therapies to treat patients with lung disease as well as a range of other diseases. Explore our research specializations to see what sets us apart from other lung institutes.
We pursue high-impact research with the ultimate goal of improving patient care and saving lives in Chicago and beyond. We invite you to learn more about the impact of our research.
Learn more about the annual Munich-Chicago Lung Conference, a partnership between Institute of Lung Health and Immunity at Helmholtz Munich and Simpson Querrey Lung Institute for Translational Science (SQLIFTS) at Northwestern.
SQLIFTS investigators are collaborating on a project to understand why age is the single most important risk factor for the development of acute and chronic lung diseases. Funded through a substantial, collaborative grant from the National Institute on Aging, our investigators seek to identify therapies that target fundamental pathways of aging to improve lung health. This project is led by institute director Scott Budinger, MD.
What if we could make the lung regenerate after injury? A large collaborative grant from the National Heart, Lung, and Blood Institute led by SQLIFTS investigators seeks to identify pathways that can be targeted to promote lung repair after viral pneumonia. This project is led by Karen Ridge, PhD.
A multi-investigator project in SQLIFTS seeks to understand why all lung transplant recipients eventually reject their lungs. This multidisciplinary program funded through a grant from the National Heart, Lung, and Blood Institute is strongly rooted in the Northwestern Medicine Lung Transplant Program, which is well known for its clinical innovation. This project is led by Ankit Bharat, MD.
Pneumonia is one of the leading causes of death from infectious disease worldwide. Richard Wunderink, MD, in SQLIFTS leads a collaborative project called the Successful Clinical Response in Pneumonia Therapy (SCRIPT) Systems Biology Center to understand why pneumonia therapies fail in some individuals and how we can improve survival.
Ravi Kalhan, MD, leads an observational research program focused on lifecourse transitions from respiratory health to chronic lung disease. In partnership with the American Lung Association, the Lung Health Cohort is the first-ever large-scale lung health study that will track 4,000 young adults (aged 25-35) at the age of peak lung health to identify predictors of a loss of lung function later in life.
The T32 grant offered through the Division of Pulmonary & Critical Care supports research in cellular and molecular pathophysiology of lung disease and the translation of these findings to the bedside. The long-term goal is to encourage bright, enthusiastic trainees to pursue a career in pulmonary biology investigation. The T32 training program is directed by Karen Ridge, PhD.
SQLIFTS is proud to announce the Neu-Lung Consortium, a newly awarded NIAID U19 Cooperative Center in Human Immunology.
Through our selected publications, learn more about key findings from SQLIFTS, including discoveries related to COVID-19, lung cancer and healthcare disparities.
Find to the code repositories for publications by SQLIFTS researchers.
The Kimberly Querrey Fellowship in Data Science supports the training and career development of exceptional MD or PhD graduates on their path to becoming successful academic leaders.
Follow SQLIFTS on Twitter